Workflow
Earnings Beat
icon
Search documents
Xcel Energy to Release Q2 Earnings: Here's What You Need to Know
ZACKS· 2025-07-25 13:41
Core Viewpoint - Xcel Energy (XEL) is expected to report its second-quarter 2025 results on July 31, following a previous quarter with a negative earnings surprise of 9.7% [1] Factors Impacting Q2 Performance - The residential electric and natural gas bills in Xcel Energy's operating regions are lower than the national average, attracting new customers and positively impacting top-line performance [2] - Increased demand from data centers, the rise of electric vehicles, and regional economic growth are also anticipated to contribute positively to earnings [3] - However, higher operation and maintenance expenses, along with increased depreciation and interest costs, may offset some of these positive factors [3] Q2 Expectations - The Zacks Consensus Estimate for earnings is set at 62 cents per share, reflecting a year-over-year increase of 14.8% [4] - Revenue is projected to reach $3.31 billion, indicating a year-over-year improvement of 9.3% [4] Earnings Prediction - The earnings model predicts a potential earnings beat for Xcel Energy, supported by a positive Earnings ESP of +1.76% and a Zacks Rank of 3 (Hold) [5][6] Other Industry Considerations - Eversource Energy (ES) and IDACORP (IDA) are also expected to report earnings beats, with respective Earnings ESPs of +0.26% and +2.34% [7][10] - Consolidated Edison (ED) is projected to have an Earnings ESP of +3.88% [10]
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
ZACKS· 2025-07-24 16:46
Core Viewpoint - Incyte Corporation (INCY) is expected to exceed expectations in its second-quarter 2025 earnings report, with revenue estimates at $1.15 billion and earnings at $1.40 per share [1]. Factors Likely to Influence INCY's Q2 Results - Incyte's primary revenue source is from its lead drug, Jakafi (ruxolitinib), with strong sales anticipated across all approved indications, although competition may limit growth [2]. - The Zacks Consensus Estimate for Jakafi's sales in Q2 is $744 million, with higher royalties expected from Novartis due to increased Jakavi sales outside the U.S. [3][4]. Sales Performance of Other Drugs - Opzelura's sales are projected to reach $149 million, driven by new patient starts and strong uptake in the EU [8]. - Additional contributions to revenue are expected from other drugs like Minjuvi, Pemazyre, and Iclusig, with respective sales estimates of $34.25 million, $20.24 million, and $28.99 million [11]. Recent Developments - The FDA approved Monjuvi for a new cancer indication, which is likely to enhance its sales performance [10]. - Niktimvo, launched in Q1 2025, recorded $13.6 million in sales, and further updates on its launch activities are anticipated [12][13]. Earnings Surprise History - Incyte has a mixed earnings surprise history, with one earnings beat in the last four quarters and an average negative surprise of 82.37% [14]. Earnings Predictions - The Earnings ESP for Incyte is +1.43%, indicating a potential earnings beat, supported by a Zacks Rank of 3 [15][16].
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
ZACKS· 2025-07-24 16:16
Core Insights - Revvity, Inc. (RVTY) is expected to report second-quarter 2025 results on July 28, with a history of earnings surprises averaging 7.71% over the last four quarters [2][4][14] Q2 Estimates - The Zacks Consensus Estimate for revenues is $711.3 million, reflecting a 2.8% increase year over year, while earnings are estimated at $1.14 per share, indicating a 6.6% decline year over year [3] - Revvity anticipates organic revenue growth of 2% to 4%, translating to total revenues between $700 million and $715 million, with gross margins expected around 60% due to tariff impacts [4][10] Diagnostics Segment - The Diagnostics segment grew 5% organically in Q1 2025, driven by high-single-digit growth in immunodiagnostics and strong performance in reproductive health [5][6] - For Q2 2025, the Diagnostics segment is projected to contribute significantly, with revenues estimated at $388.4 million, up 2.8% year over year [7][10] Life Sciences Segment - The Life Sciences segment experienced 2% organic growth in Q1 2025, supported by strong reagent demand and over 20% growth in the Signals Software business [8] - Revenues for the Life Sciences segment are estimated at $321.7 million, reflecting a 2.5% increase year over year, despite pressures from weak academic demand for instrumentation [9][10] Other Factors - Revvity's collaboration with Genomics England aims to enhance newborn genomic screening, supporting momentum in the Diagnostics segment [11] - The launch of the IDS i20 analytical platform by EUROIMMUN is expected to drive incremental revenue in the Diagnostics segment during Q2 [12] - Tariff-related headwinds are anticipated to peak in Q2, but management has implemented mitigation strategies expected to take effect in the second half of the year [13]
What's in the Cards for Unum Group This Earnings Season?
ZACKS· 2025-07-24 16:01
Core Insights - Unum Group (UNM) is expected to report second-quarter 2025 earnings on July 29, with anticipated improvements in both revenue and earnings compared to the previous year [1][2] - The Zacks Consensus Estimate for UNM's first-quarter revenues is $3.32 billion, reflecting a 2.4% growth year-over-year [1] - The consensus estimate for earnings is $2.23 per share, indicating a year-over-year increase of 3.2% despite a recent downward adjustment of 8 cents in the past 30 days [2] Earnings Prediction Model - The current Earnings ESP for UNM is -0.79%, as the Most Accurate Estimate of $2.21 is lower than the Zacks Consensus Estimate of $2.23, indicating uncertainty in predicting an earnings beat [3] - UNM holds a Zacks Rank of 3, suggesting a hold position [4] Factors Influencing Q2 Results - Premium income is projected at $2.7 billion, representing a 3% increase from the previous year, driven by favorable persistency and improved sales across operating segments [5] - Net investment income is estimated at $543.7 million, supported by higher miscellaneous investment income and increased invested assets, compared to the Zacks Consensus Estimate of $524 million [6] - Performance in Unum U.S. and Colonial Life is expected to benefit from higher premium income and improved benefit experiences across various product lines [7] Segment Revenue Estimates - Unum US operating revenues are estimated at $2 billion, while Colonial Life is projected at $501 million [8] - Unum International is expected to generate $290.2 million in operating revenues, benefiting from expansion and improved performance in its product lines [8] Expense Considerations - Total benefits and expenses are anticipated to reach $2.8 billion, influenced by increased policy benefits, commissions, and other costs [10] - Continued share buybacks are likely to positively impact the bottom line [10]
CNX Resources Q2 Earnings Beat Estimates, Revenues Increase Y/Y
ZACKS· 2025-07-24 15:11
Core Insights - CNX Resources Corporation (CNX) reported second-quarter 2025 operating earnings of 59 cents per share, exceeding the Zacks Consensus Estimate of 39 cents by 51.3% and increasing 63.9% from 36 cents in the same quarter last year [1][8] CNX's Revenues - The company reported revenues of $450 million, missing the Zacks Consensus Estimate of $457 million by 1.4%, but showing a 30.1% increase from $346 million in the prior-year quarter [2] Highlights of CNX's Q2 Release - The average selling price in the quarter was $2.68 per thousand cubic feet equivalent (Mcfe), up 3.9% from $2.58 a year ago - Total production cost was $1.67 per Mcfe, down 2.3% year over year - Total production volumes were 167.6 billion cubic feet equivalent (Bcfe), up 25.1% year over year - Interest expenses totaled $44 million, up 13.9% year over year [3][8] Share Repurchase and Debt Management - During the second quarter, CNX repurchased 3.7 million shares at an average price of $31.24 per share for a total cost of $114 million, representing approximately 40% of its outstanding shares over the past 19 quarters - CNX's adjusted net debt decreased by $69 million [4][8] Financial Update - As of June 30, 2025, CNX had cash and cash equivalents of $3.39 million, down from $17.2 million as of December 31, 2024 - Long-term debt increased to $2.29 billion from $1.84 billion as of December 31, 2024 - Cash from operating activities for the first six months of 2025 totaled $282.5 million compared to $191.8 million in the year-ago period, with free cash flow amounting to $188 million [5] Capital Expenditure - Capital expenditure for the first six months totaled $113.6 million, down from $151.9 million in the year-ago period [6] CNX's Guidance - CNX expects total capital expenditure for 2025 to be between $450 million and $500 million - The company anticipates 2025 production volume to be in the range of 615-620 Bcfe, an increase from the previous guidance of 605-620 Bcfe - Total free cash flow is expected to be $575 million [7][9]
Woodward Set to Release Q3 Earnings: Here's What to Expect
ZACKS· 2025-07-24 15:01
Core Insights - Woodward, Inc. (WWD) is set to report its third-quarter fiscal 2025 results on July 28, with revenue expectations of $887.8 million, reflecting a 4.7% increase year-over-year, while earnings per share (EPS) are projected to decline by 0.6% to $1.62 [1][9] - The company has consistently exceeded earnings estimates in the past four quarters, with an average surprise of 15.6% [1][9] Revenue and Segment Performance - The Aerospace segment is anticipated to drive performance in the fiscal third quarter, supported by growth in the commercial aftermarket and increased defense activity [4] - The Industrial segment is experiencing strong demand for power generation and backup power for data centers, with a narrowed revenue decline projection of 7-9% for fiscal 2025 [5][6] - Revenue from the Aerospace segment is expected to rise by 10.3% to $571 million, while the Industrial segment is projected to decline by 7.8% to $304.4 million for the fiscal third quarter [6] Market Challenges - The on-highway natural gas truck market in China is facing volatility, with sales reported at $21 million in the last quarter and a full-year revenue expectation of only $40 million, down significantly from $175 million in fiscal 2024 [7][8] - Global macroeconomic weakness and rising costs are additional concerns impacting WWD's Industrial performance [7][9] Recent Developments - On July 21, 2025, WWD completed the acquisition of Safran's Electronics & Defense electromechanical actuation business, enhancing its capabilities in aircraft stabilization systems [10] - WWD was selected by Airbus to supply the electro-hydraulic Spoiler Actuation System for the A350 aircraft, which includes hardware delivery and long-term maintenance services [11] Earnings Prediction - The company's earnings model indicates a likely earnings beat, supported by a positive Earnings ESP of +4.29% and a Zacks Rank of 1 (Strong Buy) [12]
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
ZACKS· 2025-07-23 15:55
Core Insights - Investors are focused on the performance of the lead drug Cabometyx as Exelixis prepares to report its second-quarter 2025 results on July 28, with sales and earnings estimates at $527 million and 63 cents per share respectively [1][6] Group 1: Earnings Performance - Exelixis has consistently beaten earnings estimates in the past four quarters, with an average surprise of 48.6%, including a 47.62% beat in the last reported quarter [2] - The company's earnings ESP is +2.52%, with the consensus estimate at 63 cents per share and the most accurate estimate at 65 cents [12] Group 2: Revenue Drivers - Revenue generation comes from net product sales, license revenues, and collaboration and service revenues, with net product revenues likely increasing due to higher Cabometyx sales volumes and average net selling prices [3] - The label expansion of Cabometyx for treating pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET) is expected to contribute to incremental sales [5][6] Group 3: Drug Performance and Market Position - Cabometyx remains the leading TKI for advanced renal cell carcinoma (RCC) in both front-line and second-line treatment settings, with this trend expected to continue [4] - The FDA's recent approvals for Cabometyx are anticipated to drive additional revenue growth in Q2 [9] Group 4: Share Repurchase and Financial Strategy - The board has authorized a $500 million stock repurchase program, which is expected to enhance the bottom line as the ongoing repurchase program is completed [7] Group 5: Pipeline Developments - Positive results from the late-stage STELLAR-303 study for zanzalintinib, a third-generation oral TKI, are expected to add momentum to the pipeline ahead of earnings [8][9]
Moody's Q2 Earnings Beat Estimates, Revenues & Expenses Rise Y/Y
ZACKS· 2025-07-23 15:36
Core Insights - Moody's reported second-quarter 2025 adjusted earnings of $3.56 per share, exceeding the Zacks Consensus Estimate of $3.44, with an 8.5% year-over-year growth [1][7] - The company's revenues improved to $1.90 billion, surpassing the Zacks Consensus Estimate of $1.85 billion, reflecting a 4.5% increase year-over-year [3][7] - Operating expenses rose to $1.08 billion, up 3.6% year-over-year, impacting overall profitability [3][7] Financial Performance - Net income attributable to Moody's was $578 million or $3.21 per share, an increase from $552 million or $3.02 per share in the prior-year quarter [2] - Adjusted operating income reached $966 million, a 7.1% increase year-over-year, with an adjusted operating margin of 50.9%, up from 49.6% a year ago [3] Segment Performance - Moody's Investors Service (MIS) revenues slightly declined to $1.06 billion due to weakness in Corporate Finance and Financial Institutions, partially offset by growth in Structured Finance [4] - Moody's Analytics (MA) revenues increased by 10.5% year-over-year to $891 million, driven by strong demand for proprietary data and analytical insights [4] Balance Sheet and Liquidity - As of June 30, 2025, Moody's had total cash, cash equivalents, and short-term investments of $2.29 billion, down from $2.97 billion as of December 31, 2024 [5] - The company reported $7 billion in outstanding debt and $1.25 billion in additional borrowing capacity under its revolving credit facility [5] Share Repurchase Activity - In the quarter, Moody's repurchased 0.6 million shares at an average price of $460.76, with $0.9 billion of share repurchase authorization remaining [6] Guidance and Outlook - Moody's updated its 2025 guidance, expecting adjusted earnings of $13.50-$14.00 per share, revised from the previous target of $13.25-$14.00 [7][8] - The MIS segment's revenue growth is now expected to be in the low to mid-single-digit range, adjusted from stable to mid-single-digit growth [8] Strategic Developments - In June, Moody's fully acquired ICR Chile, enhancing its presence in Latin America's domestic credit markets, although the transaction is not expected to materially impact 2025 financial results [9][10]
Wabtec Gears Up to Report Q2 Earnings: Is a Beat in Store?
ZACKS· 2025-07-23 14:31
Core Insights - Wabtec Corporation (WAB) is set to report its second-quarter 2025 results on July 24, with a history of positive earnings surprises, having outperformed the Zacks Consensus Estimate in three of the last four quarters, averaging a beat of 5.86% [1][4]. Earnings Performance - The Zacks Consensus Estimate for WAB's Q2 2025 earnings is $2.18 per share, reflecting a 0.46% upward revision in the past 60 days and an 11.22% increase from the previous year's actual [4][5]. - WAB's Q1 2025 earnings per share were reported at $2.28, exceeding the Zacks Consensus Estimate of $2.01, marking a 20.6% year-over-year improvement [10]. Revenue Estimates - The Zacks Consensus Estimate for WAB's Q2 2025 revenues is $2.77 billion, indicating a 4.84% growth from the previous year [5]. - Q2 2025 Freight revenues are estimated at $2.01 billion, representing a 4.6% increase year-over-year, while Transit revenues are pegged at $763 million, indicating a 5.4% growth [6][7]. Influencing Factors - The anticipated earnings performance is supported by higher sales and operating margin expansion, although supply chain issues, economic and political uncertainties, and high costs may pressure margins and revenues [4][8]. - Wabtec's operations outside the U.S. expose it to foreign currency exchange rate fluctuations, which is a significant concern for its financials [8]. Earnings Prediction Model - The current model predicts a potential earnings beat for Wabtec, supported by a positive Earnings ESP of +0.50% and a Zacks Rank of 2 (Buy) [9].
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
ZACKS· 2025-07-22 17:16
Core Viewpoint - West Pharmaceutical Services (WST) is expected to report second-quarter 2025 results on July 24, with prior performance indicating a strong earnings beat of 18.85% in the last quarter and an average surprise of 7.81% over the past four quarters [1] Q2 Estimates - The company anticipates second-quarter revenues between $720 million and $730 million, reflecting a 3% to 4% organic sales growth, with adjusted diluted earnings per share (EPS) projected at $1.50 to $1.55 [2][8] - The Zacks Consensus Estimate for revenues stands at $726 million, indicating a 3.4% growth year-over-year, while the consensus for earnings is $1.51 per share, showing a decline of 0.7% year-over-year [3] Revenue and Segment Performance - Total revenue is estimated at $722.2 million, representing a 3.2% organic improvement year-over-year, with the Proprietary Products segment expected to generate $583.5 million (4.6% organic growth) and Contract-Manufactured Products projected at $138.7 million [4] - The Proprietary Products segment is experiencing solid demand, particularly for high-value products like GLP-1-related components, which constituted over 73% of segment revenues in the first quarter [6] Segmental Analysis - Biologics within Proprietary Products is expected to show mixed but stable performance, with the SmartDose platform gaining traction, although early-quarter challenges may temper growth [7] - In Contract Manufacturing, growth in GLP-1 auto-injectors is offsetting declines from continuous glucose monitoring (CGM) products, with the Dublin facility expected to enhance drug-handling capabilities over time [9] Operational Insights - The company reported a solid first-quarter performance in 2025, with revenues of $698 million and EPS of $1.45, demonstrating resilience amid industry-wide destocking challenges [5] - Despite macro pressures and inventory dynamics, operational efficiencies and disciplined cost management are expected to support gross margins, although a softer mix of lower-margin products may weigh on performance [10] Earnings Prediction - The model predicts an earnings beat for WST, supported by a positive Earnings ESP of +0.57% and a Zacks Rank of 2 (Buy) [11][12]